MedTrace Logo

Added Value of O-RADS in Evaluation of Ovarian Lesions

NCT04579575 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-12-16

No results posted yet for this study

Summary

To detect added value of O-RADS in evaluation of ovarian lesions and compare O-RADS with GI-RADS regarding malignancy rate, the validity and reliability through pathological results and other modalities

Conditions

  • Ovarian Diseases

Interventions

DEVICE

Trans-abdominal Ultrasound

All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position. The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions. * The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system. * The definite diagnoses of AM were preferentially established based on Histo-pathological findings and other modalities.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hisham Moustafa Kamel · Assiut University

  • Haisam Ahmed Samy Aly Atta · South Egypt Cancer Institute ,Assiut University

  • Doaa Mohamed Fouad · South Egypt Cancer Institute ,Assiut University

Eligibility

Min Age
17 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2022-01-01
Completion
2022-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04579575 on ClinicalTrials.gov